The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight loss results comparable to those of popular GLP-1 injectables like ...

A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which targets both GLP-1 and amylin receptors to help control blood sugar and ...

The drug, amycretin, works by replicating two hunger hormones — amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that is ...

PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to ...

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a ...

Amycretin, a new weight loss drug developed by Novo Nordisk, has shown promising early results and is potentially more effective than the company’s established treatments, Ozempic and Wegovy.

Study participants taking amycretin reported mild to moderate side effects including nausea and vomiting. Given that the results come from such a small trial, it could take several years for ...

Novo Nordisk is very comfortable it will be able to launch the pill version of its experimental weight loss drug amycretin this decade, the drugmaker's head of development told Reuters on Friday ...

Amycretin trial showed weight loss of 9.7% to 22% over 36 weeks at varying doses, compared to weight gain with placebo. Common side effects were mild-to-moderate gastrointestinal issues, aligning ...